pdufa.bio

SL-846

Page updated ·next FDA decision on the calendar ·Data as of Nov 5, 2026 9:00 PM ET

SL-846 is a Shattuck Labs, Inc. program. Every date links its source.

STTK catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: Shattuck Labs, Inc. (STTK). We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q3 2026STTK

Specialist biotech funds holding STTK, 13F for the quarter ended June 30, 2026

FundSharesValue at quarter endFiling
Redmile Group6,892,033$47.8 millionfiled August 14, 2026
OrbiMed Advisors6,306,127$43.8 millionfiled August 14, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is SL-846's next FDA decision or readout?

No upcoming catalyst is on our calendar for SL-846; no FDA decisions are on record below.

What happened at SL-846's most recent FDA decision?

No FDA decision for SL-846 is in our archive yet.

Who makes SL-846?

Shattuck Labs, Inc. (STTK).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.